Cost of Revenue Trends: ACADIA Pharmaceuticals Inc. vs MorphoSys AG

Biopharma Cost Trends: ACADIA vs MorphoSys

__timestampACADIA Pharmaceuticals Inc.MorphoSys AG
Wednesday, January 1, 20146060200077000
Thursday, January 1, 20157636900077000
Friday, January 1, 2016440600097000
Sunday, January 1, 20171306000033000
Monday, January 1, 2018183300001796629
Tuesday, January 1, 20191959800012085198
Wednesday, January 1, 2020205500009174146
Friday, January 1, 20211914100032200000
Saturday, January 1, 20221016600048620000
Sunday, January 1, 20234573100058355000
Loading chart...

Infusing magic into the data realm

Cost of Revenue Trends: A Tale of Two Biopharma Giants

In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. This chart highlights the cost of revenue trends for ACADIA Pharmaceuticals Inc. and MorphoSys AG from 2014 to 2023. ACADIA Pharmaceuticals, known for its innovative treatments, saw a significant fluctuation in its cost of revenue, peaking in 2015 with a 76% increase from the previous year. However, by 2022, costs had decreased by 47% compared to 2015, reflecting strategic cost management.

Conversely, MorphoSys AG, a leader in antibody therapies, experienced a steady rise in costs, culminating in a 75-fold increase by 2023 compared to 2014. This surge underscores the company's aggressive expansion and investment in R&D. These trends offer a window into the strategic priorities of these companies, with ACADIA focusing on cost efficiency and MorphoSys on growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025